FDA Inspection 1176451 — Hikma Pharmaceuticals USA Inc.
The FDA completed an inspection of Hikma Pharmaceuticals USA Inc. on July 7, 2022 in Cherry Hill, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 7, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Cherry Hill, NJ (United States)